Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients

Background: High body mass index (BMI) has been associated with worse clinical outcomes in patients with early-stage breast cancer (BC), and its negative effects could be mediated by hyperglycemia/diabetes. However, the prognostic impact of high BMI in early-stage HER2-positive (HER2+) BC patients r...

Full description

Bibliographic Details
Main Authors:	Francesca Ligorio, Luca Zambelli, Achille Bottiglieri, Lorenzo Castagnoli, Emma Zattarin, Riccardo Lobefaro, Arianna Ottini, Andrea Vingiani, Serenella M. Pupa, Giulia V. Bianchi, Giuseppe Capri, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-04-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359211006960

Similar Items

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
by: Francesca Ligorio, et al.
Published: (2022-03-01)

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
by: Emma Zattarin, et al.
Published: (2020-12-01)

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
by: Francesca Ligorio, et al.
Published: (2021-04-01)

Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
by: Emma Zattarin, et al.
Published: (2022-08-01)

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness
by: Serenella M. Pupa, et al.
Published: (2021-09-01)

Antitumor activity and efficacy of shorter longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis
by: Riccardo Lobefaro, et al.
Published: (2020-12-01)

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
by: Lorenzo Castagnoli, et al.
Published: (2019-06-01)

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
by: Claudio Vernieri, et al.
Published: (2020-04-01)

Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world
by: Serena Di Cosimo, et al.
Published: (2022-09-01)

Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer
by: Claudio Vernieri, et al.
Published: (2020-03-01)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
by: Emma Zattarin, et al.
Published: (2023-04-01)

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
by: Leonardo Provenzano, et al.
Published: (2023-04-01)

Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness
by: Lorenzo Castagnoli, et al.
Published: (2020-11-01)

Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
by: Emma Zattarin, et al.
Published: (2023-12-01)

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
by: Lorenzo Ferrando, et al.
Published: (2023-01-01)

Efficacia della combinazione lapatinib-capecitabina in una paziente con carcinoma mammario HER2-positivo metastatico e con resistenza primaria a due linee di terapia con agenti anti-HER2
by: Claudio Vernieri, et al.
Published: (2017-12-01)

Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy Failure
by: Lorenzo Castagnoli, et al.
Published: (2020-02-01)

Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group
by: Luca Licata, et al.
Published: (2023-03-01)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
by: Jacopo Azzollini, et al.
Published: (2022-04-01)

Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
by: Antonino Carbone, et al.
Published: (2019-06-01)

Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors
by: Claudio Vernieri, et al.
Published: (2019-09-01)

The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse.
by: Cristina Marchini, et al.
Published: (2011-01-01)

A gene expression-based classifier for HER2-low breast cancer
by: Serena Di Cosimo, et al.
Published: (2024-02-01)

Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy
by: Serena Di Cosimo, et al.
Published: (2019-11-01)

Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer
by: Marco Silvestri, et al.
Published: (2022-01-01)

Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
by: Luigi Celio, et al.
Published: (2019-12-01)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
by: Vojnovic, B, et al.
Published: (2016)

The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
by: Natalya V. Mazurina, et al.
Published: (2021-02-01)

Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).
by: Federico Gabrielli, et al.
Published: (2013-01-01)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
by: Alessandra Raimondi, et al.
Published: (2020-08-01)

SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
by: Cristina Andreani, et al.
Published: (2023-12-01)

Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
by: Dukić Nikolina, et al.
Published: (2020-01-01)

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
by: Serena Di Cosimo, et al.
Published: (2023-01-01)

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
by: Nadine Norton, et al.
Published: (2018-06-01)

Hemiballismus in hyperglycemia
by: Agnes Kataja Knight, et al.
Published: (2021-05-01)

Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer
by: Martina Dameri, et al.
Published: (2021-07-01)

A combination of extracellular matrix‐ and interferon‐associated signatures identifies high‐grade breast cancers with poor prognosis
by: Mara Lecchi, et al.
Published: (2021-05-01)

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
by: Federico Nichetti, et al.
Published: (2019-12-01)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
by: Elisa Agostinetto, et al.
Published: (2022-04-01)

Prognostic value and relapse pattern of HER2‐low in hormone receptor‐positive breast cancer
by: Tong Wei, et al.
Published: (2024-03-01)